At a glance
ClinicalIndex Comparison RecordPhase 4Unknown· 548 enrolled
Drug / intervention
Prasugrel +3 moredrug
Likely dose
Prasugrel 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Trial of Prasugrel Plus Bivalirudin vs. Clopidogrel Plus Heparin in Patients With Acute STEMI
In Brief
A Phase 4 clinical trial evaluating Prasugrel, Bivalirudin, and 2 other interventions for Myocardial Infarction. Targeting 548 participants across 3 sites.
Detailed Summary
Randomized comparison of two different anticoagulation strategies: prasugrel plus bivalirudin versus clopidogrel plus heparin in patients with acute myocardial infarction undergoing emergency catheterization and coronary intervention.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyocardial Infarction
CountriesGermany
Collaborators--
Timeline
Phase 4UnknownOverdue
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2009
First PostedSep 2009
Primary CompletionFeb 2014
Study CompletionFeb 2015
TodayJul 2026
First PostedSep 14, 2009
Enrollment StartSep 1, 2009
Primary CompletionFeb 1, 2014
Study CompletionFeb 1, 2015
TodayJul 1, 2026
Enrollment to primary: 4.4 yearsPosted 16.8 years ago
Interventions
Prasugreldrug
60 mg prasugrel as loading dose prior to PPCI
Bivalirudindrug
IV bolus 0.75 mg/kg of body weight followed by an infusion of 1.75 mg/kg/hour during the PPCI
Clopidogreldrug
600 mg clopidogrel as loading dose before PPCI
Heparindrug
i.v. bolus of 70-100 IU/kg body weight